Hydrated lipidic lamellar phases or liposomes based on ecdysteroids

• US 5,198,225 A
• Filed: 03/22/1991
• Issued: 03/30/1993
• Est. Priority Date: 10/03/1988
• Status: Expired due to Term

• Current Assignee: Lvmh Recherche
• Original Assignee: Lvmh Recherche
• Inventors: Bonte, Frederic, Meybeck, Alain
• Primary Examiner(s): Oage, Thurman K.
• Assistant Examiner(s): KISHORE, GOLLAMUDI S
• Application Number:
  US07/671,682
• Time in Patent Office: 739 Days
• Field of Search: 424/450, 424/538, 424/195.1, 424/401, 424/417, 514/181, 514/182, 514/844, 514/887, 428/402.2
• US Class Current: 424/450
• CPC Class Codes: A61K 31/575 substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
• CPC Class Codes: A61K 8/14 Liposomes; Vesicles
• CPC Class Codes: A61K 8/63 Steroids; Derivatives thereof
• CPC Class Codes: A61K 9/127 Liposomes
• CPC Class Codes: A61Q 19/08 Anti-ageing preparations
• CPC Class Codes: Y10T 428/2984 Microcapsule with fluid core [includes liposome]

Abstract

Compositions based on hydrated lipidic lamellar phases or liposomes are disclosed containing at least in part at least one ecdysteroid or ecdysteroid derivative, in particular ecdysterone, or a plant or animal extract containing the said ecdysteroid or ecdysteroid derivative. Cosmetic or pharmaceutical compositions can be prepared as well as compositions for sericulture or a phytosanitary composition.

Claims

1. A composition comprising hydrated lipidic lamellar phases or liposomes containing at least one ecdysteroid in a concentration ranging between 0.0001 and 5% by weight of the composition.

2. The composition of claim 1, wherein the ecdysteroid is selected from the group consisting of ecdysterone, an acylated ecdysterone, an hydroxylated ecdysterone, a deoxyecdysterone, α

-ecdysone, 2-deoxyecdysone and a β

-ecdysone acetate.

3. The composition of claim 1, wherein the ecdysteroid is selected from the group consisting of ecdysterone, β

-ecdysone-2-acetate, β

-ecdysone-3-acetate, β

-ecdysone-2,3-diacetate, β

-ecdysone-2,3,22-triacetate, β

-ecdysone-2,3,22,25-tetraacetate, 5-hydroxyecdysterone, and 2-deoxyecdysterone.

4. The composition of claim 1, wherein the ecdysteroid is ecdysterone.

5. The composition of claim 1, wherein the ecdysteroid is extracted from a plant selected from the group consisting of Polypodium vulgare, Ajuga decumbens, and Cyanotis arachnoidea.

6. The composition of claim 1, wherein the ecdysteroid is at least partially incorporated into the lipidic phase of the hydrated lipidic lamellar phases or liposomes.

7. The composition of claim 6, wherein the concentration of the ecdysteroid ranges between 0.001 and 30% by weight of said lipidic phase.

8. The composition of claim 1, wherein the concentration of the ecdysteroid ranges between 0.001 and 5% by weight of the composition.

9. The composition of claim 6, wherein the concentration of the ecdysteroid ranges between 0.01 and 10% by weight of said lipidic phase.

10. A cosmetic or pharmaceutical composition comprising hydrated lipidic lamellar phases or liposomes containing at least one ecdysteroid in a concentration ranging between 0.001 and 5% by weight of the composition, in admixture with a cosmetically or pharmaceutically acceptable excipient.

11. The composition of claim 10, wherein the concentration of the ecdysteroid ranges between 0.05 and 1% by weight of the composition.

12. The composition of claim 10, wherein the ecdysteroid is selected from the group consisting of ecdysterone, an acylated ecdysterone, an hydroxylated ecdysterone, a deoxyecdysterone, β

-ecdysone, 2-deoxyecdysone and a β

-ecdysone acetate.

13. The composition of claim 10, wherein the ecdysteroid is selected from the group consisting of ecdysterone, β

-ecdysone-2-acetate, β

-ecdysone-3-acetate, β

-ecdysone-2,3-diacetate, β

-ecdysone-2,3,22-triacetate, β

-ecdysone-2,3,22,25-tetraacetate, 5-hydroxyecdysterone, and 2-deoxyecdysterone.

14. The composition of claim 10, wherein the ecdysteroid is ecdysterone.

15. The composition of claim 10, wherein the ecdysteroid is extracted from a plant selected from the group consisting of Polypodium vulgare, Ajuga decumbens, and Cyanotis arachnoidea.

16. The composition of claim 10, wherein the ecdysteroid is at least partially incorporated into the lipidic phase of the hydrated lipidic lamellar phases or liposomes.

17. The composition of claim 16, wherein the concentration of the ecdysteroid ranges between 0.001 and 30% by weight of said lipidic phase.

18. The composition of claim 16, wherein the concentration of the ecdysteroid ranges between 0.01 and 10% by weight of said lipidic phase.

19. A composition for sericulture comprising hydrated lipidic lamellar phases or liposomes containing at least one ecdysteroid in a concentration ranging between 0.0001 and 1% by weight of the composition.

20. The composition of claim 19, wherein the concentration of the ecdysteroid ranges between 0.0005 and 0.01% by weight of the composition.

21. The composition of claim 19, wherein the ecdysteroid is selected from the group consisting of ecdysterone, an acylated ecdysterone, an hydroxylated ecdysterone, a deoxyecdysterone, α

-ecdysone, 2-deoxyecdysone and a β

-ecdysone acetate.

22. The composition of claim 19, wherein the ecdysteroid is selected from the group consisting of ecdysterone, β

-ecdysone-2-acetate, β

-ecdysone-3-acetate, β

-ecdysone-2,3-diacetate, β

-ecdysone-2,3,22-triacetate, β

-ecdysone-2,3,22,25-tetraacetate, 5-hydroxyecdysterone, and 2-deoxyecdysterone.

23. The composition of claim 19, wherein the ecdysteroid is ecdysterone.

24. The composition of claim 19, wherein the ecdysteroid is extracted from a plant selected from the group consisting of Polypodium vulgare, Ajuga decumbens, and Cyanotis arachnoidea.

25. The composition of claim 19, wherein the ecdysteroid is at least partially incorporated into the lipidic phase of the hydrated lipidic lamellar phases or liposomes.

26. The composition of claim 25, wherein the concentration of the ecdysteroid ranges between 0.001 and 30% by weight of said lipidic phase.

27. The composition of claim 25, wherein the concentration of the ecdysteroid ranges between 0.01 and 10% by weight of said lipidic phase.

28. A phytosanitary composition comprising hydrated lipidic lamellar phases or liposomes containing at least one ecdysteroid in a concentration ranging between 0.0001 and 5% by weight of the composition.

29. The composition of claim 28, wherein the concentration of the ecdysteroid ranges between 0.0005 and 1% by weight of the composition.

30. The composition of claim 28, wherein the ecdysteroid is selected from the group consisting of ecdysterone, an acylated ecdysterone, an hydroxylated ecdysterone, a deoxyecdysterone, α

-ecdysone, 2-deoxyecdysone and a β

-ecdysone acetate.

31. The composition of claim 28, wherein the ecdysteroid is selected from the group consisting of ecdysterone, β

-ecdysone-2-acetate, β

-ecdysone-3-acetate, β

-ecdysone-2,3-diacetate, β

-ecdysone-2,3,22-triacetate, β

-ecdysone-2,3,22,25-tetraacetate, 5-hydroxyecdysterone, and 2-deoxyecdysterone.

32. The composition of claim 28, wherein the ecdysteroid is ecdysterone.

33. The composition of claim 28, wherein the ecdysteroid is extracted from a plant selected from the group consisting of Polypodium vulgare, Ajuga decumbens, and Cyanotis arachnoidea.

34. The composition of claim 28, wherein the ecdysteroid is at least partially incorporated into the lipidic phase of the hydrated lipidic lamellar phases or liposomes.

35. The composition of claim 34, wherein the concentration of the ecdysteroid ranges between 0.001 and 30% by weight of said lipidic phase.

36. The composition of claim 34, wherein the concentration of the ecdysteroid ranges between 0.01 and 10% by weight of said lipidic phase.

37. A method for regenerating the cutaneous structure, comprising applying to the area of the skin to be treated, in an amount sufficient to regenerate the cutaneous structure, a composition comprising hydrated lipidic lamellar phases or liposomes containing at least one ecdysteroid in a concentration ranging between 0.001 and 5% by weight of the composition.

38. The method of claim 37, for producing an anti-wrinkling effect on the skin.

39. The method of claim 37, for producing a cicatrizing effect on the skin.

40. The method of claim 37, for producing an anti-aging effect on the skin.

41. The method of claim 37, for producing a tonic effect on the hair.

42. The method of claim 37, wherein the ecdysteroid is selected from the group consisting of ecdysterone, an acylated ecdysterone, an hydroxylated ecdysterone, a deoxyecdysterone, α

-ecdysone, 2-deoxyecdysone and a β

-ecdysone acetate.

43. The method of claim 37, wherein the ecdysteroid is selected from the group consisting of ecdysterone, β

-ecdysone-2-acetate, β

-ecydysone-3acetate, β

-ecdysone-2,3-diacetate, β

-ecdysone-2,3,22-triacetate, β

-ecdysone-2,3,22,25-tetraacetate, 5-hydroxyecdysterone, and 2-deoxyecdysterone.

44. The method of claim 37, wherein the ecdysteroid is at least partially incorporated into the lipidic phase of the hydrated lipidic lamellar phases or liposomes.

45. The method of claim 44, wherein the concentration of the ecdysteroid in the lipidic phase ranges between 0.001 and 30% by weight of said lipidic phase.

46. The method of claim 44, wherein the concentration of the ecdysteroid in the lipidic phase ranges between 0.01 and 10% by weight of said lipidic phase.